Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis
- 20 July 2005
- reference entry
- Published by Wiley
- No. 3,p. CD000227
- https://doi.org/10.1002/14651858.cd000227.pub2
Abstract
Vitamin D and related compounds have been used to prevent osteoporotic fractures in older people. To determine the effects of vitamin D or related compounds, with or without calcium, for preventing fractures in older people. We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled Trials (The Cochrane Library 2007, Issue 3), MEDLINE, EMBASE, CINAHL, and reference lists of articles. Most recent search: October 2007. Randomised or quasi‐randomised trials comparing vitamin D or related compounds, alone or with calcium, against placebo, no intervention, or calcium alone, reporting fracture outcomes in older people. Two authors independently assessed trial quality, and extracted data. Data were pooled, where admissible, using the fixed‐effect model, or random‐effects model if heterogeneity between studies appeared high. Forty‐five trials were included. Vitamin D alone appears unlikely to be effective in preventing hip fracture (nine trials, 24,749 participants, RR 1.15, 95% CI 0.99 to 1.33), vertebral fracture (five trials, 9138 participants, RR 0.90, 95% CI 0.42 to 1.92) or any new fracture (10 trials, 25,016 participants, RR 1.01, 95% CI 0.93 to 1.09). Vitamin D with calcium reduces hip fractures (eight trials, 46,658 participants, RR 0.84, 95% CI 0.73 to 0.96). Although subgroup analysis by residential status showed a significant reduction in hip fractures in people in institutional care, the difference between this and the community‐dwelling subgroup was not significant (P = 0.15). Overall hypercalcaemia is significantly more common in people receiving vitamin D or an analogue, with or without calcium (18 trials, 11,346 participants, RR 2.35, 95% CI 1.59 to 3.47); this is especially true of calcitriol (four trials, 988 participants, RR 4.41, 95% CI 2.14 to 9.09). There is a modest increase in gastrointestinal symptoms (11 trials, 47,042 participants, RR 1.04, 95% CI 1.00 to 1.08, P = 0.04) and a small but significant increase in renal disease (11 trials, 46,537 participants, RR 1.16, 95% CI 1.02 to 1.33). Frail older people confined to institutions may sustain fewer hip fractures if given vitamin D with calcium. Vitamin D alone is unlikely to prevent fracture. Overall there is a small but significant increase in gastrointestinal symptoms and renal disease associated with vitamin D or its analogues. Calcitriol is associated with an increased incidence of hypercalcaemia.Keywords
This publication has 165 references indexed in Scilit:
- Distribution and Correlates of Serum 25-Hydroxyvitamin D Levels in a Sample of Patients with Hip FractureThe American Journal of Geriatric Pharmacotherapy, 2007
- Vitamin D Supplementation and Total MortalityA Meta-analysis of Randomized Controlled TrialsArchives of internal medicine (1960), 2007
- Calcium plus Vitamin D Supplementation and the Risk of FracturesNew England Journal of Medicine, 2006
- Estimates of optimal vitamin D statusOsteoporosis International, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trialBMJ, 2003
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or OlderNew England Journal of Medicine, 1997
- Efficacy of ipriflavone and 1α vitamin D therapy for the cessation of vertebral bone lossInternational Journal of Gynecology & Obstetrics, 1995
- 1,25-Dihydroxyvitamin D3(Calcitriol) in the Treatment of Postmenopausal OsteoporosisAktuelle Rheumatologie, 1994